Results 91 to 100 of about 4,386 (137)

“It's Not a One Size Fits All”: Service Users’ Views on How Service Structure Shapes Quality of Abortion Care in Britain. Findings from the SACHA Study.

Studies in Family Planning, Volume 57, Issue 3, Page 350-370, September 2026.
Abstract Abortion care in Britain has undergone significant transformation in recent years, with increasing use of medication, home management, and telemedicine. However, provision remains predominantly through specialist standalone clinics, particularly in England.
Rachel Scott, Maria Lewandowska, Rebecca Meiksin, Natasha Salaria, Patricia A. Lohr, Sharon Cameron, Jennifer Reiter, Melissa Palmer, Rebecca S. French, Kaye Wellings, the SACHA Study Team*   +10 more
wiley   +1 more source

Clinical applications of mifepristone

, 2006
Mifepristone is a progesterone antagonist that has been studied for a number of clinical applications. It is a well-known abortifacient that is effective for both first- and second-trimester medical abortion when used with a prostaglandin analog.
Ho, PC, Tang, OS
core   +1 more source

Mifepristone Antagonization With Progesterone to Prevent Medical Abortion [PDF]

, 2019
ObjectiveTo estimate the efficacy and safety of mifepristone antagonization with high-dose oral progesterone.MethodsWe planned to enroll 40 patients in a double-blind, placebo-controlled, randomized trial.
Dalton, Laura, Hou, Melody Y, Steward, Rachel, Mitchell D. Creinin, Creinin, Mitchell D, Melody Y. Hou, Melissa J. Chen, Chen, Melissa J, Rachel Steward, Laura Dalton   +9 more
core   +1 more source

Depomedroxyprogesterone acetate impact on mifepristone action during medication abortion [PDF]

PurposeTo evaluate outcomes by gestational duration in patients who did and did not receive depomedroxyprogesterone acetate (DMPA) concurrently with mifepristone for mifepristone-misoprostol medication abortion and estimate the impact of DMPA on ...
Creinin, Mitchell D, Boraas, Christy M
core   +1 more source

Neuroprotective effect of mifepristone involves neuron depolarization

, 2006
International audienceIn several regions of the developing nervous system, neurons undergo programmed cell death. In the rat cerebellum, Purkinje cell apoptosis is exacerbated when cerebellar slices are cultured during the first postnatal week.
Schumacher, M., Ghoumari, A.M., Eychenne, B., Levenes, C., Piochon, C., Dusart, I., Tomkiewicz, C., Levenes, Carole, Baulieu, E.   +8 more
core   +1 more source

Role for mifepristone in breast cancer

, 2014
Mifepristone (MFP) is an antiprogestin that has shown some beneficial effects in breast cancer clinical trials. Interestingly, progestins such as medroxyprogesterone acetate (MPA) have also been used as second or third line therapies for breast cancer ...
Molinolo, Alfredo, Sahores, Ana, Lydon, John P., Lamb, Caroline Ana, Lanari, Claudia Lee Malvina   +4 more
core   +1 more source

From Disease Silos to Integrated Cardiometabolic Care: Diabetes, Vascular Disease, and Heart Failure

Journal of Diabetes, Volume 18, Issue 9, September 2026.
Zachary T. Bloomgarden, Yehuda Handelsman   +1 more
wiley   +1 more source

Mifepristone and rapamycin have non-additive benefits for life span in mated female Drosophila

Fly
The drugs mifepristone and rapamycin were compared for their relative ability to increase the life span of mated female Drosophila melanogaster. Titration of rapamycin indicated an optimal concentration of approximately 50 μM, which increased median life
Gary N. Landis, Britta Baybutt, Shoham Das, Yijie Fan, Kate Olsen, Karissa Yan, John Tower   +6 more
doaj   +1 more source

Mifepristone for uterine fibroids

, 2009
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To determine the eLicacy and safety of Mifepristone in the management uterine fibroids in pre menopausal ...
Spies, J, Leonardo J Orozco, Peter Stone, Orozco, L, Tristan, M, James B Spies, Clarke, JF, Jane Clarke, Mario Tristán, Stone, PR   +9 more
core   +1 more source

Effects of the glucocorticoid antagonist, mifepristone, on the consequences of withdrawal from long term alcohol consumption

, 2008
BACKGROUND: Studies were carried out to test the hypothesis that administration of a glucocorticoid Type II receptor antagonist, mifepristone (RU38486), just prior to withdrawal from chronic alcohol treatment, would prevent the consequences of the ...
Croft, Adam P., Mulholland, Patrick, Little, Hilary, Prendergast, Mark A., Jacquot, Catherine, Prendergast, Mark A, Croft, Adam P, Shaw, Sidney G, Little, Hilary J., Shaw, Sidney G., Croft, Adam P.; id_orcid, Little, Hilary J   +11 more
core   +1 more source